Scholar Rock Q3 2022 Earnings Report
Key Takeaways
Scholar Rock reported a net loss of $43.3 million, with revenue at $0 for Q3 2022. The company's cash, cash equivalents, and marketable securities were approximately $343.7 million as of September 30, 2022.
Presented 24-month apitegromab data on quality-of life-measures from the TOPAZ trial and SRK-181 data from DRAGON trial at major medical/scientific congresses
Announced key leadership appointments, including Jay Backstrom as President & CEO and Jing L. Marantz as Chief Medical Officer.
Amended existing debt facility with Oxford Finance and Silicon Valley Bank, providing an additional $25 million of capacity and extending interest-only period and loan maturity date
Continued enrollment of the Phase 3 SAPPHIRE clinical trial and ongoing enrollment in DRAGON Part B.
Scholar Rock
Scholar Rock
Forward Guidance
Scholar Rock is well funded to advance its pipeline through key milestones, including completing the topline data readout from the SAPPHIRE study and progressing Part B of the DRAGON trial.